Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
Hong Kong Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be Asia’s first bladder cancer organoid biobank to chairing multicentre trials that have earned top honours from the European Association of…
Europe Cancer is becoming one of Europe’s defining public health and economic challenges, forcing policymakers to think far beyond treatment alone. Questions of prevention, screening, innovation, equitable access, system resilience, and global competitiveness are now increasingly intertwined. Elisabetta Zanon discusses how the European Cancer Organisation is working to keep patients at…
USA For many years, the US has been considered the unequivocal champion in the global war against cancer. Not only does the country presently account for approximately 57 percent of worldwide cancer research funding, but American per capita investment in oncology research averages as much as seven times higher than that…
Japan Asia is emerging as a critical frontier in oncology research, yet much of global drug development continues to overlook the region’s specific clinical needs. At the National Cancer Center Japan, Kenichi Nakamura is working to change that dynamic through ATLAS, a pan-Asian clinical trial network designed to enable more coordinated,…
USA Jeff Allen is the President & CEO of Friends of Cancer Research, a research policy and advocacy organisation based in Washington, DC. His organisation works to accelerate the development of cancer therapies through evidence-based policy and collaborative research partnerships. Allen highlights the importance of diagnostics and biomarker testing to help…
France France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left by private industry and the state while elevating the concerns of the most important people within healthcare: patients and their…
Global Ahead of this year’s International Women’s Day on March 8th, Unjela Kaleem highlights the disproportionate impact of cancer on women, especially those in developing countries. Kaleem – drawing on 20+ years of experience in healthcare strategic communications – argues that celebrating women’s economic empowerment while ignoring the cancers that take…
Taiwan Dr John Chang, Chief Executive Officer of the Formosa Cancer Foundation and a distinguished medical oncologist at Chang Gung Memorial Hospital, provides a comprehensive strategic analysis of Taiwan’s oncology landscape. He delineates the evolution of precision medicine, the economic intricacies of national health reimbursement, and the critical role of patient…
China EnCureGen’s founder Dr Aimin Hui draws on a career spanning oncology, molecular biology and global R&D leadership to pursue the next generation of mRNA therapeutics. His role in driving the Fosun-BioNTech COVID-19 collaboration shaped his belief that mRNA can extend far beyond infectious disease, and from Guangzhou International Bio Island…
France Professor Jean-Yves Blay stands as a distinguished figure in contemporary oncology, serving simultaneously as a practising medical oncologist, cancer researcher, and institutional leader. Currently director general of a comprehensive cancer centre and president of the French Federation of Comprehensive Cancer Centres, he has also held pivotal roles, including Director of…
Global Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’ Pluvicto, RLT has proved its potential. But are current regulatory frameworks and healthcare systems prepared to integrate this less-than-typical therapy?…
See our Cookie Privacy Policy Here
